185 related articles for article (PubMed ID: 23207045)
1. Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Hong TS; Wo JY; Kwak EL
Semin Radiat Oncol; 2013 Jan; 23(1):31-7. PubMed ID: 23207045
[TBL] [Abstract][Full Text] [Related]
2. Esophagogastric cancer: targeted agents.
Ku GY; Ilson DH
Cancer Treat Rev; 2010 May; 36(3):235-48. PubMed ID: 20122806
[TBL] [Abstract][Full Text] [Related]
3. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
5. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
6. Isolated CNS relapse in human epidermal growth factor receptor 2-positive esophagogastric cancer: effective treatment with trastuzumab after failure of surgery and radiotherapy.
Geldart T; Astras G
J Clin Oncol; 2011 Aug; 29(23):e664-5. PubMed ID: 21646609
[No Abstract] [Full Text] [Related]
7. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
Varadhachary G; Ajani JA
Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in gastroesophageal cancer.
Kasper S; Schuler M
Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan S; Prabhakar D; Sharma N
Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
[TBL] [Abstract][Full Text] [Related]
10. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
11. Cancer of the gastroesophageal junction: combined modality therapy.
Ilson DH
Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
[TBL] [Abstract][Full Text] [Related]
12. Emerging mAbs for the treatment of esophagogastric cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
[TBL] [Abstract][Full Text] [Related]
13. [Toward more understanding of esophagogastric cancer].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):801-3. PubMed ID: 22335942
[No Abstract] [Full Text] [Related]
14. Molecular targeted agents for gastric and gastroesophageal junction cancer.
Oshima T; Masuda M
Surg Today; 2012 Apr; 42(4):313-27. PubMed ID: 22127535
[TBL] [Abstract][Full Text] [Related]
15. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
[No Abstract] [Full Text] [Related]
16. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
17. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
[TBL] [Abstract][Full Text] [Related]
19. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
20. Targeting the human EGFR family in esophagogastric cancer.
Okines A; Cunningham D; Chau I
Nat Rev Clin Oncol; 2011 Apr; 8(8):492-503. PubMed ID: 21468131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
